Eris Lifesciences acquires Strides Shasun’s India branded generics biz for $77m

In its fourth and largest acquisition in the last 18 months, Ahmedabad-based Eris Lifesciences Ltd has acquired Strides Shasun Ltd‘s India branded generics business for a cash consideration of  Rs 500 crore ($77 million).

Strides’ India branded generics business comprises a portfolio of over 130 brands in the domains of neurology, psychiatry, nutraceuticals, gastro among others, along with the employees in the business. This business had sales of Rs 181 crore in 2016-17.

“Eris will acquire the marketing and distribution rights for the said portfolio of products in India while Strides will retain the global rights for these products,” the two companies said in a joint statement.

The transaction is scheduled to be close by November 30, 2017.

Bengaluru-based Shasun Strides plans to use the funds to re-pay its debt of around Rs 400 crore ($61.5 million).

“This transaction is the outcome of our portfolio reprioritization, to focus more sharply on larger regulated markets. We retain global rights for the divested portfolio, which have significant sales in Africa and will continue to grow our emerging market business,” said Shashank Sinha, Managing Director of Strides Shasun.

For Strides, MAPE Advisory Group and Tatva Legal acted as the transaction advisor and legal advisor respectively.

EY India was the exclusive M&A advisor and Shardul Amarchand Mangaldas & Co was the legal advisor to Eris Lifesciences on this transaction.

Founded in 2007, drugs manufacturer Eris Lifesiences debuted on the stock exchanges in June this year, where in its founders and other shareholders sold stoke. Private equity major ChrysCapital sold its entire 16.25 per cent  stake through the IPO.

It recently acquired utraceuticals maker UTH Healthcare Ltd for Rs 12.85 crore ($1.96 million). In August 2016,  it had signed a pact with Amay Pharmacuticals Pvt. Ltd to acquire trademarks of 40 brands for Rs 32.87 crore. After which, in December last year Eris had increased its stake in Kinedex Healthcare Pvt. Ltd 75.48 per cent from from 61.48 per cent.

Also Read:

Eris Lifesciences acquires UTH Healthcare for $2m

India: CDSL’s $81m IPO subscribed 170 times on last day

Strides Shasun acquires Australian operations of Amneal Pharma for $13.5m

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.